derinet® Switzerland
Back

27.00% p.a. Barrier Reverse Convertible on BioNTech, Johnson & Johnson, Moderna, Novavax, Pfizer

  • Valor 113443527
  • ISIN CH1134435275
  • Symbol RMBJ6V
Bid (indicative)%
Nominal
Ask (indicative)%
Nominal
CurrencyUSD
Price on
Sell
Buy
  • (Issuer) Callable
Johnson & JohnsonUSD 
Pfizer Inc.USD 
Moderna Inc.USD 
BioNTech SEUSD 
Novavax Inc.USD 
Please note that this is an indication.

Documents

Key data
Yield max.33.83%
Yield max. p.a.34.16%
Barrier reachedno
Interest
Coupon (Coupon p.a.)27.00% (27.00%)
Premium component26.7540%
Interest share0.246%
Day count convention30/360
Pricingdirty
Life cycle
Initial fixing01/10/2021
First Trading Day05/10/2021
Payment date06/10/2021
Final fixing03/10/2022
Redemption11/10/2022

Current price information

Intraday1 weekSince emission
until
Product Underlying

Loading data

Performance
UnderlyingClosing PriceStrike PriceBarrier
USD 247.68USD 254.79USD 140.13
USD 161.30USD 160.47USD 88.26
USD 324.21USD 341.09USD 187.60
USD 161.95USD 181.60USD 99.88
USD 41.49USD 42.93USD 23.61

No chart available

Key data
Yield max.33.83%
Yield max. p.a.34.16%
Barrier reachedno
Interest
Coupon (Coupon p.a.)27.00% (27.00%)
Premium component26.7540%
Interest share0.246%
Day count convention30/360
Pricingdirty
Life cycle
Initial fixing01/10/2021
First Trading Day05/10/2021
Payment date06/10/2021
Final fixing03/10/2022
Redemption11/10/2022
Figures
SSPA categorisationBarriere Reverse Convertible
Issue price100.00%
Nominal valueUSD 1,000.00
Reference currencyUSD
QuantoNo
Strike price

Reference price of the underlying used to calculate the cash settlement on expiry of the warrant. In cases of physical delivery it is the price at which the underlying is bought (call) or sold (put). Also called: exercise price

100.00%
Barrier55.00%
Barrier observationcontinuous
ListingSIX Structured Products Exchange
Additional conditions
IssuerVontobel Financial Products Ltd., DIFC Dubai
GuarantorVontobel Holding AG, Zurich
Lead ManagerBank Vontobel AG, Zurich
Redemption / deliveryphysical delivery
Issuance ProgrammeLink to the Issuance Program